Status:

RECRUITING

RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).

Lead Sponsor:

University Medical Center Mainz

Conditions:

Esophageal Adenocarcinoma

Eligibility:

All Genders

18-90 years

Phase:

NA

Brief Summary

BACKGROUND: For patients with esophageal cancer, radical esophagectomy with 2-field lymphadenectomy is the cornerstone of the multimodality treatment with curative intent. Both, conventional minimally...

Detailed Description

Aim of the study This is a randomized controlled parallel-group, superiority trial comparing RAMIE to MIE with intrathoracic anastomosis (Ivor-Lewis) in patients with resectable esophageal adenocarcin...

Eligibility Criteria

Inclusion

  • Histologically proven adenocarcinoma of the intrathoracic esophagus and gastroesophageal junction (including Siewert I and II)
  • Surgically resectable (T1-4a, N0-3, M0)
  • Age ≥ 18 and ≤ 90 years
  • European Clinical Oncology Group (ECOG) performance status 0,1 or 2
  • Written informed consent

Exclusion

  • Esophageal squamous cell carcinoma
  • Carcinoma of the cervical esophagus
  • Carcinoma of the gastro-esophageal junction (GEJ) with the main part of the tumor in the gastric cardia (Siewert type III)
  • Prior thoracic surgery at the right hemithorax or thoracic trauma

Key Trial Info

Start Date :

January 18 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 19 2028

Estimated Enrollment :

218 Patients enrolled

Trial Details

Trial ID

NCT04306458

Start Date

January 18 2021

End Date

January 19 2028

Last Update

May 17 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Medical Center Mainz

Mainz, Germany, 55131

RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial). | DecenTrialz